Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter
Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter
Stereotaxis Inc (NYSE:STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE:ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation systems.
Stereotaxis and Abbott have completed the integration of their technologies and performed testing demonstrating joint compatibility.
The integrated technologies are cleared for use in Europe, with additional regulatory clearances expected in the coming months.
Concurrently, the FDA approved Abbott's TactiFlex Ablation Catheter, Sensor Enabled. The company says it is the world's first ablation catheter with a flexible tip and contact force technology.
It is used to perform an ablation procedure to treat atrial fibrillation (AFib), the most common abnormal heart rhythm. The TactiFlex catheter can result in reduced procedure times and better safety than the company's previous-generation catheters.
The TactiFlex catheter uses a tip design with a laser-cut pattern that flexes when in contact with the heart wall, thus helping direct fluid to the treated tissue and allowing for more accurate positioning of the catheter – providing up to two times higher stability in a beating heart – for consistent therapy delivery.
Tuesday, the FDA approved Abbott's spinal cord stimulation devices for chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
Price Action: STXS shares are up 34.7% at $2.28, and ABT shares are up 0.34% at $108.84 on the last check Friday.
Stereotaxis Inc (NYSE:STXS) shares are gaining after the company announced a global collaboration with Abbott Laboratories (NYSE:ABT) to integrate Abbott's EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation systems.
Stereotaxis 紐約證券交易所代碼：STXS）宣佈與該公司進行全球合作後，股價上漲 雅培實驗室 （紐約證券交易所代碼：ABT）將雅培的enSite X EP系統與Stereotaxis的機器人磁導航系統集成。
Stereotaxis and Abbott have completed the integration of their technologies and performed testing demonstrating joint compatibility.
Stereotaxis和Abbott已經完成了其技術的整合，並進行了測試，證明了聯合兼容性。
The integrated technologies are cleared for use in Europe, with additional regulatory clearances expected in the coming months.
集成技術已獲准在歐洲使用，預計未來幾個月將獲得更多監管許可。
Concurrently, the FDA approved Abbott's TactiFlex Ablation Catheter, Sensor Enabled. The company says it is the world's first ablation catheter with a flexible tip and contact force technology.
同時，美國食品藥品管理局批准了雅培的TactiFlex消融導管，支持傳感器。該公司表示，這是世界上第一款採用柔性尖端和接觸力技術的消融導管。
It is used to perform an ablation procedure to treat atrial fibrillation (AFib), the most common abnormal heart rhythm. The TactiFlex catheter can result in reduced procedure times and better safety than the company's previous-generation catheters.
它用於進行消融手術以治療心房顫動 (Afib)，這是最常見的心律異常。與該公司的上一代導管相比，TactiFlex導管可以縮短手術時間並提高安全性。
The TactiFlex catheter uses a tip design with a laser-cut pattern that flexes when in contact with the heart wall, thus helping direct fluid to the treated tissue and allowing for more accurate positioning of the catheter – providing up to two times higher stability in a beating heart – for consistent therapy delivery.
TactiFlex 導管採用具有激光切割圖案的尖端設計，該圖案在與心臟壁接觸時會彎曲，從而有助於將液體引導到治療後的組織，並允許更準確地定位導管，從而在跳動的心臟中提供高達兩倍的穩定性，從而實現穩定的治療。
Tuesday, the FDA approved Abbott's spinal cord stimulation devices for chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
週二，美國食品藥品管理局批准了 雅培的 脊髓刺激設備，用於治療未接受或沒有資格接受背部手術的人的慢性背部疼痛，稱爲非手術性背部疼痛。
Price Action: STXS shares are up 34.7% at $2.28, and ABT shares are up 0.34% at $108.84 on the last check Friday.
價格走勢： 在週五的最後一張支票中，STXS股價上漲34.7％，至2.28美元，ABT股價上漲0.34％，至108.84美元。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧